logo

BOLT

Bolt Biotherapeutics·NASDAQ
--
--(--)
--
--(--)
3.04 / 10
Netural

Comprehensive review: 3.0/10 score signifies poor fundamentals. Optimistic factors: Interest coverage ratio (EBIT / Interest expense) (%) and Profit-MV, despite concerns regarding Total operating revenue (YoY growth rate %) and Operating revenue (YoY growth rate %). Resulting view: constrained.

Fundamental(3.04)SentimentTechnical

Analysis Checks(5/10)

Revenue-MV
Value-2.81
Score1/3
Weight9.72%
1M Return4.24%
Total operating revenue (YoY growth rate %)
Value-32.44
Score1/3
Weight-1.41%
1M Return-0.79%
Days sales outstanding
Value72.55
Score1/3
Weight-2.66%
1M Return-1.57%
Profit-MV
Value0.46
Score2/3
Weight19.32%
1M Return8.45%
Net income-Revenue
Value-0.17
Score2/3
Weight19.34%
1M Return8.45%
PB-ROE
Value2.08
Score3/3
Weight26.20%
1M Return12.83%
Interest coverage ratio (EBIT / Interest expense) (%)
Value15.48
Score2/3
Weight-1.93%
1M Return-1.11%
Operating revenue (YoY growth rate %)
Value-32.44
Score1/3
Weight-1.36%
1M Return-0.76%
Asset-MV
Value-0.50
Score0/3
Weight13.80%
1M Return5.75%
Cash-MV
Value-0.07
Score2/3
Weight18.99%
1M Return8.41%
Is BOLT undervalued or overvalued?
  • BOLT scores 3.04/10 on fundamentals and holds a Fair valuation at present. Backed by its -59.90% ROE, -821.58% net margin, -0.26 P/E ratio, 0.35 P/B ratio, and 34.93% earnings growth, these metrics solidify its Netural investment rating.